TeamedOn

Executive Summary

TeamedOn International, Inc. is a private biopharmaceutical company based in San Francisco, California, focused on developing gene therapies for rare diseases, particularly inherited retinal disorders (IRDs) and other ophthalmic indications with significant unmet medical need. Founded in 2020, the company leverages innovative gene therapy approaches to address the underlying genetic causes of vision loss and other debilitating conditions. Its lead programs target a range of retinal degenerations where current treatment options are limited or nonexistent, aiming to provide durable and potentially curative therapies for patients. Given the company's early stage of development, TeamedOn is likely advancing its lead candidates through preclinical studies and preparing for regulatory interactions. While no specific pipeline data are publicly available, the company's focus on established gene therapy platforms and its location in a major biotech hub suggest it is actively building toward clinical milestones. Key near-term value drivers include progress toward Investigational New Drug (IND) applications and the potential for orphan drug designations. TeamedOn represents a speculative but high-potential opportunity within the gene therapy landscape for rare eye diseases.

Upcoming Catalysts (preview)

• Q1 2027Initiation of Phase 1/2 Clinical Trial for Lead Gene Therapy Candidate30% success
• Q2 2026Receipt of Orphan Drug Designation from FDA70% success
• Q4 2026Presentation of Preclinical Data at Ophthalmic Conference50% success